Genzyme's Synvisc retains high reimbursement rate
421111
Genzyme Corp.  said on Friday its osteoarthritis pain treatment Synvisc will retain a separate, higher reimbursement rate, after the U.S. government reversed its earlier decision to cut the rate, sending Genzyme shares higher.
401679
Genzyme Corp. suffered an unaccustomed defeat yesterday when shareholders in Bioenvision Inc. , a small New York cancer-drug developer, blocked a $350 million takeover bid by refusing to sell their stock to the Cambridge biotechnology giant.
447460
Biotechnology company Genzyme Corp   reported a fourth-quarter profit on Wednesday,  reversing a year-earlier loss, as sales of its drugs for rare  diseases increased.
643395
Genzyme Corp. hasn't given up on plans to buy Bioenvision Inc., one of its most important partners, despite mounting shareholder complaints that Genzyme's offer is too low.
451993
Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease.
312721
The biotechnology company reported fourth-quarter net income of $201.2 million on strong sales of its two leading drugs, Rituxan and Avonex.
159194
Treatment with Synagis (palivizumab), a type of antibody therapy, is not a cost effective way of preventing infection with respiratory syncytial virus (RSV) in high-risk infants, according to two new reports published in the medical journal Pediatrics.
754072
Genzyme Corp.'s planned takeover of New York cancer drug maker Bioenvision Inc. has already hit a bump: A key Bioenvision shareholder is calling the deal a lowball offer and digging in against it.
764507
Biotechnology company Genzyme Corp. said Thursday that it will buy back most of the selling rights to arthritis treatment Synvisc from pharmaceutical giant Wyeth.
412704
NEW YORK (CBS.MW) -- The Food and Drug Administration has approved Genzyme Corp. and Bioenvision Inc.&#39;s treatment for the most common type of childhood leukemia, sending shares of both companies higher Wednesday.
713941
GlaxoSmithKline Plc  has bought global rights to Danish biotech company Genmab's  most promising new drug, a treatment for leukemia, in a record deal worth up to $2.1 billion, the two firms said on Tuesday.
507775
By Tricia Bishop, The Baltimore Sun  Dec. 14--One of MedImmune Inc.'s major shareholders is urging the state's flagship biotech to put itself up for sale, suggesting management hasn't made the most from its assets, which include four products on the market and about 40 in the pipeline.
485103
Genzyme Corp.  said on Friday its experimental drug tolevamer, a treatment for diarrhea associated with the intestinal infection Clostridium difficile, worked no better than a standard antibiotic, sending the company's shares down more than 5 percent in early trading.
96500
Genzyme Corp. , the biotech firm expanding into the market for cancer treatments, said fourth-quarter revenue rose 23 percent to $591 million on higher sales of its Cerezyme treatment for Gaucher disease. Revenue increased from $481 million a year earlier, the Cambridge company said in an e-mailed statement. Profit for the full year 2004, excluding some items, rose to $1.75 ...
359683
A Johnson & Johnson JNJ.N  promotion for rheumatoid arthritis drug Remicade is misleading  because it makes unsupported claims about the drug's  effectiveness and omits important information about risks, U.S.  regulators said in a letter released on Monday.
536259
Genzyme Corp.'s not-yet-completed $1 billion acquisition of Ilex Oncology Inc. appeared to pay off yesterday when an advisory committee to the Food and Drug Administration recommended the agency approve Ilex's experimental cancer treatment for children with certain types of leukemia.
232342
Genzyme (GENZ :Nasdaq - news - research) shares rose early Wednesday after US regulators approved its leukemia drug for children. The Food and Drug Administration Tuesday approved the drug Clolar, an intravenous